<DOC>
	<DOCNO>NCT00432510</DOCNO>
	<brief_summary>The study objective describe pharmacokinetics ( PK ) one two dos C1 esterase inhibitor ( C1INH-nf ) hereditary angioedema ( HAE ) subject experience HAE attack .</brief_summary>
	<brief_title>Pharmacokinetics C1 Esterase Inhibitor Hereditary Angioedema Subjects</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Enrolled LEVP20051 ( current past ) C1 inhibitor infusion within last 7 day Signs HAE attack HAE attack within 7 day actual infusion C1INHnf Change dosage androgen last 14 day study Use antifibrinolytics last 7 day study Change oral conceptive medication last two month study History clinically relevant antibody development C1 inhibitor Use oral anticoagulant medication last 14 day Use heparin within last two day prior study History allergic reaction C1 inhibitor blood product Current participation ( within past 90 day ) investigational drug study sponsor Lev Pharmaceuticals Pregnancy lactation Bcell malignancy Any clinically significant medical condition , renal failure , opinion investigator would interfere subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hereditary angioedema</keyword>
	<keyword>C1 esterase inhibitor ( human )</keyword>
</DOC>